Enclomiphene vs Primobolan
Well Studied vs Well Studied
avoid Mechanism-based · 64% Both Enclomiphene and Primobolan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Enclomiphene Primobolan
Weight 405.96 Da 302.45 Da (base)
Half-life ~10 hours ~10 days (enanthate)
Type Trans-isomer of clomifene (selective estrogen receptor modulator) DHT-derivative steroid (C20H30O2)
Key Benefits
Enclomiphene
01 Raises endogenous testosterone by stimulating the HPTA axis
02 Preserves fertility and spermatogenesis (unlike exogenous testosterone)
03 No estrogenic agonist activity (unlike racemic clomifene/Clomid)
04 Oral dosing with no injections required
05 Does not suppress the HPTA or cause testicular atrophy
06 Effective for post-cycle therapy and secondary hypogonadism
07 Well-tolerated with a favorable side effect profile
Primobolan
01 Lean muscle mass preservation during caloric deficits with minimal water retention
02 Does not aromatize to estrogen, eliminating estrogen-related side effects
03 One of the mildest androgenic profiles among anabolic steroids, with reduced risk of acne, aggression, and prostate issues
04 Injectable form is non-hepatotoxic, allowing extended cycle durations
05 Strong anti-catabolic properties through glucocorticoid receptor modulation
06 Immune-enhancing effects at moderate therapeutic doses
07 Quality, keepable muscle gains without the bloated appearance common with aromatizing steroids
08 Compatible with long cycle lengths (16-20 weeks) due to mild overall impact on health markers
Dosing Protocols
Enclomiphene
12.5-25mg oral daily / Once daily (morning preferred)
Primobolan
400-800 mg/week (injectable) or 50-100 mg/day (oral) / 1-2x per week (enanthate) or daily (oral acetate)
Lean Mass Preservation - Cutting 400-600 mg/week 2x per week (split dose)
Lean Bulking 600-800 mg/week 2x per week (split dose)
Female Protocol 50-100 mg/week 1x per week
Side Effects
Enclomiphene
Headache
Nausea or mild gastrointestinal discomfort
Hot flashes or flushing
Mood changes (irritability or emotional sensitivity)
Fatigue during initial adjustment
Primobolan
Suppression of natural testosterone production (dose-dependent, less suppressive than many other anabolic steroids but still significant)
Hair thinning or accelerated male pattern baldness (DHT derivative -- this is the most commonly reported side effect in susceptible individuals)
Adverse lipid changes, particularly HDL suppression (moderate compared to other anabolic steroids)
Mild acne or oily skin (less pronounced than testosterone or other androgens)
Injection site discomfort from larger oil volumes required at performance doses
Gradual decline in natural testosterone production requiring post-cycle therapy
Contraindications
Known hypersensitivity to clomifene or enclomiphene
Pre-existing liver disease or significantly elevated liver enzymes
Active or history of thromboembolic disorders
Pregnancy or women who may become pregnant (teratogenic risk)
Primary hypogonadism (testicular failure -- enclomiphene requires functional testes)
Pituitary tumors or undiagnosed pituitary pathology
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males or females
Pregnancy or potential for pregnancy (teratogenic risk -- fetal virilization)
Severe hepatic impairment (particularly relevant for oral acetate form)
Known hypersensitivity to metenolone or formulation components
Hypercalcemia
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled cardiovascular disease or severe dyslipidemia
Research Evidence
Enclomiphene Primobolan
Status Well Studied Well Studied
References 5 studies 4 studies
Latest — January 2017
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.